Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
Ultragenyx Pharmaceutical Inc. (RARE) had Cash Flow from Financial Activities of $13.00M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
$173.00M |
|
$-118.00M |
|
$32.00M |
|
$141.00M |
|
$283.00M |
|
$-110.00M |
|
$-17.00M |
|
$-127.00M |
|
$-127.00M |
|
$-118.00M |
|
$-118.00M |
|
$-118.00M |
|
$-118.00M |
|
$-110.00M |
|
$-101.00M |
|
102.10M |
|
102.10M |
|
$-1.16 |
|
$-1.16 |
|
| Balance Sheet Financials | |
$544.00M |
|
$231.00M |
|
$643.00M |
|
$1.19B |
|
$389.00M |
|
-- |
|
$1.17B |
|
$1.56B |
|
$-376.00M |
|
$-590.00M |
|
$-376.00M |
|
101.90M |
|
| Cash Flow Statement Financials | |
$-337.00M |
|
$53.00M |
|
|
Cash Flow from Financial Activities |
$13.00M |
$436.00M |
|
$164.00M |
|
$-272.00M |
|
$98.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.40 |
|
-- |
|
-- |
|
-- |
|
-- |
|
81.50% |
|
-63.58% |
|
-63.58% |
|
-- |
|
-73.41% |
|
-68.21% |
|
$-341.00M |
|
-- |
|
-- |
|
-- |
|
0.15 |
|
0.54 |
|
1.04 |
|
86.36 |
|
31.38% |
|
20.00% |
|
-9.94% |
|
31.38% |
|
$-3.69 |
|
$-3.34 |
|
$-3.30 |
|